Signal
Oruka’s long-acting psoriasis drug shows strong phase 2a results, raising blockbuster potential
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-27 14:08 UTCUpdated 2026-04-27 16:12 UTC
rss
clinical_trialsdrug_developmentbiotech_funding
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Oruka Therapeutics reported that its long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, outperforming AbbVie’s Skyrizi in potency and offering less frequent dosing. Jefferies analysts forecast the drug could generate up to $10 billion in sales.
Entities
Oruka TherapeuticsAbbVie
Score total
1.01
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Phase 2a data release confirms early clinical success, attracting investor and analyst attention.
- Oruka’s share price surged 30%, reflecting market optimism about the drug’s potential.
- The timing coincides with ongoing competition in the psoriasis treatment market, emphasizing the need for new therapies.
Why it matters
- The drug’s strong efficacy and less frequent dosing could improve patient adherence and outcomes in plaque psoriasis.
- Potential to disrupt AbbVie’s dominance in the psoriasis treatment market with a more potent alternative.
- Significant sales forecasts highlight the commercial importance of innovative psoriasis therapies.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Oruka’s long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial.
- Jefferies analysts forecast the drug could generate up to $10 billion in sales, potentially surpassing AbbVie’s Skyrizi.
- Oruka’s share price surged 30% to $89.50 following the phase 2a data release.
How sources frame it
- Jefferies Analysts: supportive
Consolidated two recent reports highlighting Oruka’s phase 2a psoriasis drug data and market impact.
All evidence
All evidence
Oruka surges as long-acting psoriasis drug shows early promise
BioPharma Dive · biopharmadive.com · 2026-04-27 16:12 UTC
Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict the asset could beat ...
Fierce Biotech · fiercebiotech.com · 2026-04-27 14:08 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)